Abstract
The loss of dopaminergic cells during Parkinson's disease (PD) produces "frontal"-like impairment in spatial working memory (SWM) and planning functions. This study investigated whether an alpha2-adrenergic agonist, clonidine (0.5 or 2 microg/kg, orally), improves SWM, spatial short-term or spatial recognition memory, and planning functions in PD patients. Clonidine 2 microg/kg decreased errors in SWM, but a lower dose, 0.5 microg/kg, had no effect on performance. Clonidine 0.5 and 2 microg/kg failed to improve the strategy used to solve the SWM test. Clonidine 0.5 and 2 microg/kg had no effect on accuracy of performance in the other tests. These results showed that clonidine improves performance in a test of SWM and that this is not due to improved spatial short-term or spatial recognition memory or planning functions. The authors suggest that stimulation of alpha2-adrenoceptors improves the mnemonic processing required for accurate SWM performance in PD patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
